CompletedNCT07001475
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
A short description of this study’s research objective has not yet been verified.
Medication studyAges 18–45GermanyPersonality disorders
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Berlin, Germany · Bonn, Germany and 5 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo described in the protocol; its role is not resolved here
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: August 12, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 78
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Germany
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT07001475
- Official title
- A Phase Ib, Multicentre, Randomised, Double Blind, Placebo Controlled, 2 Sequence Crossover Trial to Evaluate the Effects of BI 3031185 on Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Recruitment & locations
CompletedBerlin · Bonn · Frankfurt am Main
4 more locations
- Halle
- Mainz
- Mannheim
- Tübingen
Registry details
Registry conditions (original wording)
Borderline Personality Disorder; Attention Deficit Hyperactivity Disorder
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including BI 3031185 and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01243658
"The Effects of Oxytocin on people with Borderline Personality Disorder"
This study is completed. It focuses on personality disorders and currently lists study information in Germany.
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2011-000210-19
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.